Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by FredTheVoiceon Apr 04, 2019 8:08am

318 Views

Post# 29580610

Heres the maths for TROGARZO since the start

second quarter 2018: first month of sales: 1 186 000 $C;
third quarter 2018: first full quarter of sales: 4 864 000 $C;
fourth quarter 2018: 5 561 000 $C;

ALL YEAR 2018 total: 11 611 000 $.

And for the fist quarter UP 44%.......SO .... 8 007 840 $.

That adds up. And looks good. But we need to do the work !!!!!

FTV.

Bullboard Posts

Unique Battery Metals opportunity in Quebec